Temporal trends of device-related infection in de novo transvenous implantable cardioverter-defibrillator Medicare patients with underlying kidney disease

Mikhael F. El-Chami*, Bradley P. Knight, Yiyan Liu, Amy J. Brisben, M. Rizwan Sohail, Robert I. Griffiths

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Kidney disease is a risk factor for device infection in transvenous implantable cardioverter-defibrillator (TV-ICD) implants, with mechanisms that include immunodeficiency and a portal of entry for bacteria that can seed indwelling devices. Objective: The purpose of this study was to examine the impact of both kidney disease and dialysis-dependence on the incidence of device-related infection after de novo TV-ICD implantation and how the incidence changes over time in. Methods: Medicare 100% administrative and claims data were used to identify patients who underwent de novo TV-ICD implantation between July 1, 2016, and December 31, 2018. Baseline characteristics included underlying kidney disease (none, nondialysis, dialysis) plus device infection during follow-up. Patients were followed for TV-ICD infection up to 78 weeks after implantation. Piecewise Poisson regression was used to predict the incidence of and hazard ratios for infection over time. Results: Overall, 809 of 42,200 patients (1.9%) had at least 1 device infection during mean follow-up of 66 weeks: 484 of 31,217 (1.6%) none; 202 of 9151 (2.2%) nondialysis; and 123 of 1832 (6.7%) dialysis (P <.001 via log-rank test). The incidence of infection increased during the first 8–12 weeks and declined thereafter. Hazard ratios increased over time (dialysis week 12 = 4.9/1000 patient-years; week 52 = 9.8; nondialysis week 12 = 1.4; week 52 = 2.5; all P <.05), as did the difference in cumulative incidence compared with none (dialysis week 12 = Δ11.8 and week 78 = Δ53.5; nondialysis week 12 = Δ1.4 and week 78 = Δ7.0). Conclusion: The incidence of infection after de novo TV-ICD implantation is higher when patients have kidney disease and is substantially higher when patients are dialysis-dependent.

Original languageEnglish (US)
Pages (from-to)1689-1695
Number of pages7
JournalHeart rhythm
Volume19
Issue number10
DOIs
StatePublished - Oct 2022

Funding

Disclosures: Dr El-Chami reports being a consultant for Boston Scientific, Medtronic, and Biotronik. Dr Knight reports being a consultant for Abbott, Biosense Webster, Biotronik, Boston Scientific, CVRx, Medtronic, and Sanofi; speaker for Abbott, Biosense Webster, Biotronik, Boston Scientific, CVRx, Medtronic, and Sanofi; and investigator for Abbott, Biosense Webster, Biotronik, Boston Scientific, CVRx, Medtronic, and Sanofi; and receiving fellowship support from Abbott , Biosense Webster , Biotronik , Boston Scientific , CVRx , Medtronic , and Sanofi . Dr Liu reports being an employee of, and having stock in, Boston Scientific Corporation. Dr Brisben reports being an employee of, and having stock in, Boston Scientific Corporation. Dr Griffiths reports being an employee of, and having stock in, Boston Scientific Corporation. Dr Sohail reports that he has no relationships relevant to the contents of this paper to disclose.

Keywords

  • Cardiac device-related infection
  • Chronic kidney disease
  • Dialysis
  • Implantable cardioverter-defibrillator
  • Infection
  • Kidney insufficiency
  • Percutaneous coronary intervention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint

Dive into the research topics of 'Temporal trends of device-related infection in de novo transvenous implantable cardioverter-defibrillator Medicare patients with underlying kidney disease'. Together they form a unique fingerprint.

Cite this